<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546843</url>
  </required_header>
  <id_info>
    <org_study_id>KDAR FN Brno</org_study_id>
    <nct_id>NCT02546843</nct_id>
  </id_info>
  <brief_title>Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population</brief_title>
  <acronym>PedLapBlock</acronym>
  <official_title>Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KDCHOT FN Brno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brno University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study prospectively evaluates our experience with administration of&#xD;
      cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various&#xD;
      depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy&#xD;
      with low-pressure capnoperitoneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized study prospectively evaluates our experience with administration of&#xD;
      cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various&#xD;
      depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy&#xD;
      with low-pressure capnoperitoneum.&#xD;
&#xD;
      After meeting inclusion criteria the patients will be randomized - - use of opaque envelopes,&#xD;
      randomization into groups A and B in an operating theatre, study blinded for the patient (or&#xD;
      his/her legal guardian) and surgeon.&#xD;
&#xD;
      Group A - muscle relaxation using rocuronium followed by sugammadex reversal (in a dose&#xD;
      according to TOF - (train-of-four) 2-4mg/kg), depth of muscle relaxation TOF 0 PTC&#xD;
      (post-tetanic count) 0-1 Group B - muscle relaxation using cisatracurium followed by&#xD;
      decurarization (neostigmine 0.03 mg/kg and atropine 0.02 mg/kg)&#xD;
&#xD;
      Anesthesia management:&#xD;
&#xD;
        -  intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol&#xD;
           2.0mg/kg and in Group A - rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid&#xD;
           sequence induction), in Group B - cisatracurium 0.15mg/kg&#xD;
&#xD;
        -  orotracheal intubation, combined anesthesia using sevoflurane - MAC (minimal alveolar&#xD;
           concentration) 1.0 with respect to the age of the patient&#xD;
&#xD;
        -  ventilation: PCV (pressure-controlled ventilation ), PEEP (positive end-expiratory&#xD;
           pressure) +5 cm H2O (aqua), normocapnia, FiO2 (fraction of inspired oxygen ) 1.0 until&#xD;
           the intubation, afterwards 0.4 + AIR&#xD;
&#xD;
        -  nasogastric tube placement&#xD;
&#xD;
      Management of neuromuscular blockade:&#xD;
&#xD;
      Group A - maintaining of deep muscular blockage - according to TOF 0, PTC 0-1, boluses of&#xD;
      rocuronium 0.3 mg/kg are allowed Group B - maintaining of muscular relaxation TOF 1, boluses&#xD;
      of cisatracurium 0.03 mg/kg are allowed Laparoscopy - capnoperitoneum pressure - 10 mmHg with&#xD;
      a reduction to 8 mmHg if possible&#xD;
&#xD;
      During the surgery the surgical conditions will be scored by using Surgical scoring system:&#xD;
      (1-2 surgeons involved):&#xD;
&#xD;
        1. Optimal conditions: there is a wide laparoscopic field, no movements or contractions&#xD;
&#xD;
        2. Good conditions: there is a wide laparoscopic field with singular movements or muscle&#xD;
           contractions&#xD;
&#xD;
        3. Acceptable conditions: there is a wide laparoscopic field but muscle contractions and/or&#xD;
           movements occur regularly. Additional neuromuscular blocking agent is required.&#xD;
&#xD;
        4. Poor conditions: the same as in grade 3 and in addition, there is a hazard of tissue&#xD;
           damage.&#xD;
&#xD;
        5. Extremely poor conditions: the surgeon cannot work because of weak muscle relaxation,&#xD;
           the patient is coughing. Additional neuromuscular blocking agent is essential.&#xD;
&#xD;
      Recovery from anesthesia:&#xD;
&#xD;
        -  extubation - TOF 0.9 - using sugammadex in Group A (2-4 mg/kg according to the depth of&#xD;
           muscle relaxation) or decurarization in Group B (atropine 0.02 mg/kg and neostigmine&#xD;
           0.03mg/kg)&#xD;
&#xD;
        -  after standard 2-hour monitoring in the recovery room (heart rate, blood pressure, SpO2&#xD;
           (oxygen saturation by pulse oximetry), level of consciousness, PONV), patients will be&#xD;
           observed in the intensive care unit for at least 24 hours Statistical analysis:&#xD;
           (provided by IBA MUNI - Institute of biostatistic and analyses by Masaryk University&#xD;
           Brno, Czech Republic)&#xD;
&#xD;
        -  demographic parameters - age, gender, type and duration of surgery&#xD;
&#xD;
        -  induction to general anesthesia - time until intubation (recognition of the capnogram&#xD;
           curve)&#xD;
&#xD;
        -  ventilation - changes in the inspiratory pressure during capnoperitoneum, increase of&#xD;
           EtCO2 (end-tidal CO2)&#xD;
&#xD;
        -  capnoperitoneal pressure&#xD;
&#xD;
        -  surgical scoring system&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical scoring system</measure>
    <time_frame>intraoperatively</time_frame>
    <description>During the surgery the blinded surgeon will grade surgical conditions due to surgical scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>intraoperatively</time_frame>
    <description>The adverse events will be monitored</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).&#xD;
maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.&#xD;
Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.&#xD;
Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.&#xD;
Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisatracurium</intervention_name>
    <description>cisatracurium 0.15mg/kg intravenously</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Nimbex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nonspecific Neuromuscular Blockade reversal</intervention_name>
    <description>neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Specific Neuromuscular Blockade reversal</intervention_name>
    <description>Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintaining the depth of neuromuscular blockade - rocuronium</intervention_name>
    <description>repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>neuromuscular blockade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintaining the depth of neuromuscular blockade - cisatracurium</intervention_name>
    <description>repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>neuromuscular blockade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pediatric patients aged 2 to 17 years (+ 364 days) eligible for laparoscopy&#xD;
             (diagnostic laparoscopy, appendectomy, cholecystectomy, nephrectomy, splenectomy,&#xD;
             tumor biopsy, varicocele correction, testicular retention)&#xD;
&#xD;
          -  fasting of at least 6 hours&#xD;
&#xD;
          -  ASA (American Society of Anesthesiology score) score 1 or 2&#xD;
&#xD;
          -  signed informed consent of the legal guardian of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  disagreement of the patient or his/her legal guardian&#xD;
&#xD;
          -  serious comorbidities - renal or hepatic disorders&#xD;
&#xD;
          -  ASA score ≥ 3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Štourač, MD, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>KDAR FN Brno</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Brno - FN Brno</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 5, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brno University Hospital</investigator_affiliation>
    <investigator_full_name>Petr Štourač, MD</investigator_full_name>
    <investigator_title>MD,Ph.D</investigator_title>
  </responsible_party>
  <keyword>rocuronium</keyword>
  <keyword>sugammadex</keyword>
  <keyword>pediatric anesthesia</keyword>
  <keyword>cisatracurium</keyword>
  <keyword>surgical conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Atracurium</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

